Can Patients With Controlled Rheumatoid Arthritis Taper Methotrexate From Targeted Therapy and Sustain Remission? A Systematic Review and Metaanalysis.

Charis F MengDiviya A RajeshDeanna P Jannat-Khah Bridget Jivanelli Gatto Vivian P Bykerk

Published in: The Journal of rheumatology (2022)

Patients with controlled RA may taper MTX from targeted therapy with a 10% reduction in the ability to sustain remission for up to 18 months. Longer follow-up studies with attention to radiographic, functional, and patient-reported outcomes are needed. The risk of disease worsening should be discussed with the patient with careful follow-up and prompt retreatment of disease worsening.

Keyphrases

rheumatoid arthritis
disease activity
patient reported outcomes
systemic lupus erythematosus
ankylosing spondylitis
working memory
interstitial lung disease
high dose
idiopathic pulmonary fibrosis